

2020

## The Role of CBX5 in Head and Neck Cancer Cell Phenotypic Expression

Kegan Main OMS-2

*Marian University - Indianapolis*

John Zemkewicz

*Marian University - Indianapolis*

Colleen L. Doci Ph.D

*Marian University - Indianapolis*

Follow this and additional works at: [https://mushare.marian.edu/mucom\\_rd](https://mushare.marian.edu/mucom_rd)



Part of the [Medicine and Health Sciences Commons](#)

---

### Recommended Citation

Main, Kegan OMS-2; Zemkewicz, John; and Doci, Colleen L. Ph.D, "The Role of CBX5 in Head and Neck Cancer Cell Phenotypic Expression" (2020). *MU-COM Research Day*. 170.

[https://mushare.marian.edu/mucom\\_rd/170](https://mushare.marian.edu/mucom_rd/170)

This Poster is brought to you for free and open access by the College of Osteopathic Medicine at MUShare. It has been accepted for inclusion in MU-COM Research Day by an authorized administrator of MUShare. For more information, please contact [emandity@marian.edu](mailto:emandity@marian.edu).





# The Role of CBX5 in Head and Neck Cancer Cell Phenotypic Expression



Kegan Main<sup>1</sup>, John Zemkewicz<sup>1</sup> and Dr. Colleen L. Doci, Ph.D.<sup>2</sup>

<sup>1</sup>College of Osteopathic Medicine, Marian University Indianapolis


<sup>2</sup>College of Health Sciences, Marian University Indianapolis

## SUMMARY

- Head and neck squamous cell carcinomas (HNSCCs) have remained one of the common and lethal cancers around the world.
- HNSCC rapidly spread via the lymphatics system, leading to a higher percentage of initial late-stage diagnoses and poor prognoses for patients.
- CBX5 is downregulated highly metastatic breast cancers and may repress metastatic phenotypes
- It is unclear what role it may have in HNSCC, or which specific functions of CBX5 drive its antimetastatic role.
- We aim to map molecular changes to phenotypic expression in order to provide better diagnostic prognoses for different HNSCC cell types as well as possible pharmacologic targets for treatment.


**HYPOTHESIS: Heterochromatin binding by CBX5, but not dimerization or ligand activation, is necessary to suppress in vitro metastasis in HNSCC cell lines.**

## REGIONAL METASTASIS SIGNIFICANTLY DECREASES SURVIVAL AND IS ASSOCIATED WITH NEGATIVE TREATMENT OUTCOMES




**Figure 1.** HNSCC rates are on the decline overall as are many cancers, however, the survivability of HNSCC has not significantly changed over time unlike other cancer subtypes.

## Angiolymphatic Invasion




**Figure 2.** Comparison of angiolymphatic invasion between N0- and N0+ patients. The clinical significance suggests that the genes that control the vascularity of tumors may be the strongest candidates for biomarker diagnosis in primary HNSCC tumors.

## CBX5 IS DOWNREGULATED IN AGGRESSIVE HNSCC




**Figure 3.** CD31 staining of blood vessels of HNSCC primary tumors in mice, which helped determine which HNSCC metastatic cell lines were vascular and avascular.




**Figure 4.** The CAL27 and UMSSC17B cell lines are metastatic vascular and appear to have lower constitutive expression of CBX5 than the HN12, and HN6 lines which are metastatic avascular


## DISSECTING CBX5 FUNCTION THROUGH MUTATIONS



**I165E**  
Disrupts homodimerization




**V22M**  
Disrupts heterochromatin binding to H3K9




**W174A**  
Disrupts CBX5 ligand binding

## INTRODUCTION OF CBX5 POINT MUTATIONS



**Figure 5.** Induction of the V22M point mutation interrupts CBX5's ability to recognize the heterochromatin and bind to it. V22M-1 also had an additional unplanned mutation resulting in a frameshift and resultant total knockdown of CBX5 expression which fortuitously can be used as a negative control.

## CBX5 GATEWAY CLONING



**Figure 6.** After early restriction digests showed a failed attempt to introduce I165E mutations we proceeded to only clone our V22M and W174A mutants to send for sequencing. In a preliminary restriction digest all 4 V22M mutants had correct lengths, and three W174A mutants were the correct length. These 7 were then sent for genetic sequencing to verify the correct mutations were present

## ACKNOWLEDGEMENTS

We would like to thank the Marian University and the MU College of Osteopathic Medicine for this opportunity and research equipment.